News
Actemra Approved for Treatment of Hospitalized COVID-19 Patients
Actemra (tocilizumab) is an interleukin-6 receptor antagonist.
Your search for supplemental oxygen returned 38 results
News
FDA Authorizes Emergency Use of Kineret for Certain Hospitalized COVID-19 Patients
Kineret is an interleukin-1 receptor antagonist.
News
Olumiant Approved for COVID-19 Treatment in Hospitalized Adults
The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.
Drugs in the Pipeline
Tocilizumab Gets Priority Review for Treatment of Hospitalized COVID-19 Patients
The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.
Drugs in the Pipeline
Lilly Ends Baricitinib Lupus Program, Provides Update on Atopic Dermatitis sNDA
Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.
News
Tocilizumab Shortage Prompts Temporary REMS Change for CAR T-Cell Therapy
Shortly after an EUA was issued, Genentech announced that tocilizumab (marketed under the brand name Actemra) was in shortage.
Drugs in the Pipeline
Baricitinib Alone Authorized for COVID-19 Under Revised EUA
The update was based on data from the COV-BARRIER study.
News
FDA Authorizes Emergency Use of Actemra for COVID-19
The EUA was issued based on 4 randomized controlled clinical trials that evaluated the efficacy and safety of Actemra in more than 5500 hospitalized patients with COVID-19.
Drugs in the Pipeline
Mixed Results for Baricitinib in Trial of Hospitalized COVID-19 Patients
Findings showed that the trial did not meet statistical significance on the primary endpoint.
Drugs in the Pipeline, News
FDA Issues EUA to Baricitinib Plus Remdesivir for Hospitalized COVID-19 Patients
The EUA was granted based on data from the phase 3 ACTT-2 trial, which was conducted by the NIAID.
